Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium
2013 · Journal of Drug Assessment · 73 citations
https://doi.org/10.3109/21556660.2013.766197
J
Juergen Jauernig
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
208
Citations
7
h-index
6
i10-index
Juergen Jauernig is an academic researcher from Novartis (Switzerland). The author has contributed to research in topics: Inhalation and Respiratory Drug Delivery & Asthma and respiratory diseases & Respiratory and Cough-Related Research. The author has an h-index of 7, co-authored 12 publications.
Papers by this author
worksPerformance Characteristics of Breezhaler® and Aerolizer® in the Real-World Setting
2021 · Clinical Drug Investigation · 17 citations
https://doi.org/10.1007/s40261-021-01021-w
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
2022 · Advances in Therapy · 11 citations
https://doi.org/10.1007/s12325-021-02025-w
Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma
2021 · Pulmonary Pharmacology & Therapeutics · 8 citations
https://doi.org/10.1016/j.pupt.2021.102068
Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients
2020 · Respiratory Research · 6 citations
https://doi.org/10.1186/s12931-020-01501-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat